Dysmorphic features: An important clue to the diagnosis and severity of fetal anticonvulsant syndromes

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 91, Issue 2, 2006, Pages

  Kini, U ^a   Adab, N ^b   Vinten, J ^b   Fryer, A ^c   Clayton Smith, J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Fazakerley   (United Kingdom)

^c ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; AORTA COARCTATION; ARTICLE; CHILD; CHILD GROWTH; CLEFT LIP; CLEFT PALATE; CONTROLLED STUDY; DEFORMITY; EPILEPSY; FACE DYSMORPHIA; FACE MALFORMATION; HEART VENTRICLE SEPTUM DEFECT; HEMANGIOMA; HUMAN; HYDROCEPHALUS; HYPOSPADIAS; INFANT; INTELLIGENCE QUOTIENT; IRIS COLOBOMA; KIDNEY DUPLICATION; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; OPTIC DISK ANOMALY; PATENT DUCTUS ARTERIOSUS; PHENOTYPE; PHOTOGRAPHY; PHYSICAL EXAMINATION; POLYDACTYLY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PYLORUS STENOSIS; SCORING SYSTEM; SPINA BIFIDA; TERATOLOGY; THYROGLOSSAL DUCT CYST;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ANTHROPOMETRY; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; DEVELOPMENTAL DISABILITIES; EPILEPSY; FACIES; FEMALE; GROWTH; HUMANS; INFANT; INTELLIGENCE; MATERNAL-FETAL EXCHANGE; NEUROPSYCHOLOGICAL TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SYNDROME; VALPROIC ACID;

EID: 33644647980     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2004.067421     Document Type: Article

References (22)

1. Dean JC, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002;39:251-9.
2. Mawer G, Clayton-Smith J, Coyle H, et al. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002;11:512-18.
3. Dieterich E, Steveling A, Lukas A, et al. Congenital anomalies in children of epileptic mothers and fathers. Neuropaediatrics 1980;11:274-83.
4. Clayton-Smith J, Donnai D. Fetal valproate syndrome. J Med Genet 1995;32:724-7.
5. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994;271:767-70.
6. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996;75:517-20.
7. Granstrom ML, Gaily E. Psychomotor development in children of mothers with epilepsy. Neurology 1992;42(suppl 5): 144-8.
8. Dolk H. Epidemiologic approaches to identifying environmental causes of birth defects. Am J Med Genet 2004;125C:4-11.
9. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-83.
10. Astfey SJ, Clarren SK. A case definition and photographic screening tool for the facial phenolype of fetal alcohol syndrome. J Paediatr 1996;129:33-41.
11. Pearson MA, Hoyme HE, Seaver LH, et al. Toluene embryopathy: delineation of the phenotype and comparison with fetal alcohol syndrome. Paediatrics 1994;93:211-15.
12. DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984;19:473-81.
13. Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988;29:171-85.
14. Winter RM, Donnai D, Burn J, et al. Fetal valproate syndrome: is there a recognisable phenotype? J Med Genet 1987;24:692-5.
15. Jones KL, Lacro RV. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. New Engl J Med 1989;320:1661-6.
16. Gaily E. Distal phalangeal hypoplasia in children with prenatal phenytoin exposure: results of a controlled anthropometric study. Am J Med Genet 1990;35:574-8.
17. Kozma C. Valproic acid embyopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001;98:168-75.
18. Omtzigt JG, Los C, Grobbee FJ, et al. The risk of spina bifida aperta after first trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl5):119-25.
19. Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-46.
20. Vanoverloop D, Schnell RR, Harvey EA, et al. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 1992;14:329-35.
21. Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 1976;89:662-8.
22. Dean JC, Moore SJ, Turnpenny PD. Developing diagnostic criteria for the fetal anticonvulsant syndromes. Seizure 2000;9:233-4.